| scholarly article | Q13442814 |
| P50 | author | Nicolas Kon Kam King | Q89471302 |
| P2093 | author name string | Lester Lee | |
| Beng Ti Ang | |||
| Angela An Qi See | |||
| Samantha Ya Lyn Ang | |||
| Ting Yao Ang | |||
| P2860 | cites work | Mutations in a putative global transcriptional regulator cause X-linked mental retardation with alpha-thalassemia (ATR-X syndrome) | Q24311995 |
| An integrated genomic analysis of human glioblastoma multiforme | Q24648860 | ||
| IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas | Q24656269 | ||
| The 2007 WHO classification of tumours of the central nervous system | Q24685772 | ||
| MGMT gene silencing and benefit from temozolomide in glioblastoma | Q27824832 | ||
| MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951. | Q27851529 | ||
| ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis | Q27852494 | ||
| International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors | Q30426724 | ||
| Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. | Q30542081 | ||
| Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. | Q34446549 | ||
| Somatic mutations in glioblastoma are associated with methylguanine-DNA methyltransferase methylation. | Q35741879 | ||
| Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p | Q35834029 | ||
| IDH mutation and MGMT promoter methylation in glioblastoma: results of a prospective registry | Q36562205 | ||
| Detection of ATRX and IDH1-R132H immunohistochemistry in the progression of 211 paired gliomas | Q37086042 | ||
| Immunohistochemical Analysis of ATRX, IDH1 and p53 in Glioblastoma and Their Correlations with Patient Survival. | Q37110440 | ||
| Personalized treatment strategies in glioblastoma: MGMT promoter methylation status | Q37221207 | ||
| The definition of primary and secondary glioblastoma | Q38064831 | ||
| A practical review of prognostic correlations of molecular biomarkers in glioblastoma | Q38366346 | ||
| The Effect of Molecular Diagnostics on the Treatment of Glioma | Q38743781 | ||
| The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary | Q38829244 | ||
| Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT. | Q38931930 | ||
| IDH1/2 Mutation and MGMT Promoter Methylation - the Relevant Survival Predictors in Czech Patients with Brain Gliomas | Q39098158 | ||
| The combined EGFR protein expression analysis refines the prognostic value of the MGMT promoter methylation status in glioblastoma | Q39567171 | ||
| Environmental risk factors for primary malignant brain tumors: a review | Q40720873 | ||
| Prognostic significance of histomolecular subgroups of adult anaplastic (WHO Grade III) gliomas: applying the 'integrated' diagnosis approach | Q40993120 | ||
| Immunohistochemical profiles of IDH1, MGMT and P53: practical significance for prognostication of patients with diffuse gliomas | Q41756350 | ||
| IDH1/IDH2 mutations define the prognosis and molecular profiles of patients with gliomas: a meta-analysis | Q42096951 | ||
| Is the prognostic significance of O6-methylguanine- DNA methyltransferase promoter methylation equally important in glioblastomas of patients from different continents? A systematic review with meta-analysis | Q42364418 | ||
| The Role of ATRX in Glioma Biology | Q42369808 | ||
| ATRX immunostaining predicts IDH and H3F3A status in gliomas | Q42701263 | ||
| NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide | Q43245397 | ||
| Significance of complete 1p/19q co-deletion, IDH1 mutation and MGMT promoter methylation in gliomas: use with caution. | Q43411833 | ||
| Status of O⁶ -methylguanine-DNA methyltransferase [MGMT] gene promoter methylation among patients with glioblastomas from India | Q44389429 | ||
| Glioblastoma survival in the United States improved after Food and Drug Administration approval of bevacizumab: a population-based analysis | Q44661518 | ||
| O(6) -methylguanine-DNA methyltransferase (MGMT) promoter methylation and low MGMT-encoded protein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radio | Q44838622 | ||
| Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma | Q46796397 | ||
| Ethnicity delineates different genetic pathways in malignant glioma | Q46839039 | ||
| Promoter Hypermethylation of the DNA Repair Gene O6‐Methylguanine‐DNA Methyltransferase is an Independent Predictor of Shortened Progression Free Survival in Patients with Low‐grade Diffuse Astrocytomas | Q48311590 | ||
| Glioblastoma multiforme in an Asian population: evidence for a distinct genetic pathway | Q48365352 | ||
| IDH mutation and MGMT promoter methylation are associated with the pseudoprogression and improved prognosis of glioblastoma multiforme patients who have undergone concurrent and adjuvant temozolomide-based chemoradiotherapy | Q48469496 | ||
| MGMT promoter hypermethylation and its associations with genetic alterations in a series of 350 brain tumors | Q48686096 | ||
| Co-deletion of 1p/19q as Prognostic and Predictive Biomarker for Patients in West Bohemia with Anaplastic Oligodendroglioma | Q49064634 | ||
| Mutant IDH1 cooperates with ATRX loss to drive the alternative lengthening of telomere (ALT) phenotype in glioma. | Q52353898 | ||
| Current Challenges and Opportunities in Treating Glioblastoma. | Q52579808 | ||
| Malignant glioma: the involvement of loss of allelic heterozygosity and PTEN mutations in a group of Malay patients. | Q54646758 | ||
| Mutant ATRX: uncovering a new therapeutic target for glioma. | Q55456861 | ||
| Clinical correlation of MGMT protein expression and promoter methylation in Chinese glioblastoma patients. | Q55463316 | ||
| Molecular Markers of Therapy-Resistant Glioblastoma and Potential Strategy to Combat Resistance. | Q55663256 | ||
| A note on quantifying follow-up in studies of failure time | Q71721709 | ||
| CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011-2015 | Q93177223 | ||
| P433 | issue | 1 | |
| P921 | main subject | biomarker | Q864574 |
| P304 | page(s) | 79 | |
| P577 | publication date | 2020-01-31 | |
| P1433 | published in | BMC Cancer | Q326300 |
| P1476 | title | Incidence of biomarkers in high-grade gliomas and their impact on survival in a diverse SouthEast Asian cohort - a population-based study | |
| P478 | volume | 20 |
| Q98291666 | Prognostic Nomograms for Primary High-Grade Glioma Patients in Adult: A Retrospective Study Based on the SEER Database | cites work | P2860 |
Search more.